Pharmacokinetic characterisation of a valproate Autism Spectrum Disorder rat model in a context of co-exposure to α-Hexabromocyclododecane.
Environ Toxicol Pharmacol
; 105: 104343, 2024 Jan.
Article
in En
| MEDLINE
| ID: mdl-38122861
ABSTRACT
Assessing the role of α-hexabromocyclododecane α-HBCDD as a factor of susceptibility for Autism Spectrum disorders by using valproic acid-exposed rat model (VPA) required characterizing VPA pharmacokinetic in the context of α-HBCDD-co-exposure in non-pregnant and pregnant rats. The animals were exposed to α-HBCDD by gavage (100 ng/kg/day) for 12 days. This was followed by a single intraperitoneal dose of VPA (500 mg/kg) or a daily oral dose of VPA (500 mg/kg) for 3 days. Exposure to α-HBCDD did not affect the pharmacokinetics of VPA in pregnant or non-pregnant rats. Surprisingly, VPA administration altered the pharmacokinetics of α-HBCDD. VPA also triggered higher foetal toxicity and lethality with the PO than IP route. α-HBCDD did not aggravate the embryotoxicity observed with VPA, regardless of the route of exposure. Based on this evidence, a single administration of 500 mg/kg IP is the most suitable VPA model to investigate α-HBCDD co-exposure.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prenatal Exposure Delayed Effects
/
Autism Spectrum Disorder
/
Hydrocarbons, Brominated
Limits:
Animals
/
Female
/
Humans
/
Pregnancy
Language:
En
Journal:
Environ Toxicol Pharmacol
/
Environ. toxicol. pharmacol
/
Environmental toxicology and pharmacology
Year:
2024
Document type:
Article
Country of publication:
Países Bajos